Spero Therapeutics, Inc.

GSK intends to file for US approval of the oral carbapenem antibiotic tebipenem-HBr to treat complicated urinary tract infections (cUTI) during the second half of 2025, three years after Spero Therape

GSK’s Blujepa (gepotidacin) is the first new mechanism of action to address uncomplicated urinary tract infections (uUTIs) in more than 30 years. The US Food and Drug Administration approved Blujepa o

Pharmaceutical companies have a variety of strategic options available to them to restock pipelines and ensure continued innovation. In terms of external innovation, in-licensing assets from other com

Two and a half months after its first US Food and Drug Administration approval for Incyte Corp.-partnered Niktimvo (axatilimab-csfr) in chronic graft-versus-host disease (GVHD), Syndax Pharmaceuticals